Physician profile
Tiffany E Smith
NPI 1154576981
$1,003.71
in general payments reported to CMS, 2019-2025
15 companies · $346 in 2025
The $346 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $56.16 · 2023: $367 · 2024: $235 · 2025: $346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $947.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $172.10 | 2023-2025 | |
| Lilly USA, LLC | $168.12 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Idorsia Pharmaceuticals US INC | $159.46 | 2022-2024 | Quviviq |
| Novo Nordisk INC | $154.69 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $72.53 | 2024-2025 | Otezla, Repatha, Repatha |
| Azurity Pharmaceuticals, INC. | $58.68 | 2023-2025 | Azmiro, Adthyza |
| Abbott Laboratories | $46.18 | 2023-2024 | Freestyle Libre, Freestyle Libre 3 |
| Galderma Laboratories, L.P. | $45.75 | 2023-2024 | Dysport |
| Tolmar, INC. | $26.79 | 2023-2024 | |
| Verity Pharmaceuticals INC. | $22.07 | 2025 | Tlando |
| Pfizer INC. | $19.30 | 2023 | |
| Ibsa Pharma INC. | $15.19 | 2023 | Tirosint, Licart |
| Halozyme INC | $14.40 | 2023 | |
| Antares Pharma, INC. | $14.36 | 2025 | Xyosted |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.